NCT00213720

Terminated

Treatment of Subclinical Hyperthyroidism

University Hospital, Strasbourg, France Source

University Hospital, Strasbourg, France

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

3463

Study Type

observational

Actual enrollment (reported)

145

Locations

1 country

Sites

21

Timeline

Study Start

August 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

November 2019

Actual (reported)

Study Completion

January 2020

Actual (reported)

Brief Summary

Objective: To determine if the treatment of subclinical hyperthyroidism will reduce the rate of atrial fibrillation, the main complication of this condition.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Actual enrollment (reported): 145 participants
Study completion date: January 2020
Actual (reported)
Listed locations: 1 countries · 21 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 13, 2005
Actual (reported)
First Posted
September 21, 2005
Actual (reported)
Primary Completion
November 2019
Actual (reported)
Study Completion
January 2020
Actual (reported)

Last Updated: September 29, 2020
Status Verified: August 2019
Last Update Submitted: September 25, 2020

Conditions

Atrial Fibrillation Subclinical Hyperthyroidism

Keywords

Hyperthyroidismatrial fibrillationquality of liferadioiodine treatment

Eligibility Criteria

Age50 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

patients referred to tertiary hospitals for advice on thyroïd disease

You may qualify if:

Men and women aged 50 and greater
Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels

You may not qualify if:

Iodide overload
Non sinusal heart rhythm

Sponsors & Collaborators

University Hospital, Strasbourg, France
Otherlead

Study Sites (21)

Patrick Roger

Bordeaux, France

Philippe Thiéblot

Clermont-Ferrand, France

Jean-Marcel Brun

Dijon, France

Jean-Louis Wemeau

Lille, France

Marie-Pierre Teissier

Limoges, France

Jacques Orgiazzi

Lyon, France

Bernard Conte-Delvox

Marseille, France

CH de Montbrison

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Atrial FibrillationHyperthyroidism

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsThyroid DiseasesEndocrine System Diseases

Study Officials

Bernard Goichot, MD
Hopitaux Universitaires de Strasbourg
PRINCIPAL INVESTIGATOR

Enrollment

145 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 21, 2005

Study Start

August 2005

Date type not reported

This date has not been verified as actual or estimated.

SYFc819c3969ac7430dbb635bc692d5ead9

Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation.

Phase 2Not Yet Recruiting

NCT03388658

Safety and Efficacy of Cryoballoon Pulmonary Vein Isolation : a Single Center Registry

Completed

NCT00265629

RF Ablation of Atrial Fibrillation

Phase 1Completed

NCT00115843

Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring

Not ApplicableWithdrawn

NCT00255281

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

Phase 2Completed

NCT00419640

SAFE Study - Septal Pacing for Atrial Fibrillation Suppression Evaluation

Not ApplicableCompleted

Severe heart disease

Contact the study team to confirm eligibility.

Montbrison, 42605, France

Jacques Bringer

Montpellier, France

Marc Klein

Nancy, France

Michel Rodier

Nîmes, France

Laurence Leenhardt

Paris, France

Richard Marechaud

Poitiers, France

Brigitte Delemer

Reims, France

Claire Schvartz

Reims, France

Jean-Marc Kuhn

Rouen, France

Bruno Estour

Saint-Etienne, France

Centre Paul Strauss

Strasbourg, 67000, France

Hopitaux Universitaires de Strasbourg

Strasbourg, France

Philippe Caron

Toulouse, France

Pierre Lecomte

Tours, France

Primary Completion

November 2019

Actual (reported)

Study Completion

January 2020

Actual (reported)

Last Updated

September 29, 2020

Record last verified: 2019-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00213720
Data provider: ClinicalTrials.gov
Source updated: 2020-09-29
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:19:13 UTC

Locations

FR(21)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (21)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations